Startup Juno raises $120m for 'unprecedented' immunotherapies
This article was originally published in Scrip
The size of Juno Therapeutics's Series A venture funding round is a bright neon sign illuminating the drug development industry's growing enthusiasm for immunotherapies that can train patients' immune systems to attack cancer cells.
You may also be interested in...
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Private Company Edition: Former Juno execs launch allogeneic cell therapy venture Sana, Atlas raises a $250m fund, and the Rakuten Aspyrian, Apollomics and Antengene VC deals exceed the $100m mark.
The drug showed favorable but not significant trends across secondary endpoints, and greater efficacy in slower-progressing patients and those treated earlier in the disease, in a small subpopulation.